GLP-1 status: the answers, dated and sourced

As of Oct 3, 2026, FDA says semaglutide is not on its drug shortage list or the 503B bulks list, so pharmacies may compound it only under the ordinary limits of sections 503A and 503B; the shortage-era grace periods ended in 2025.

As of Oct 3, 2026, FDA says tirzepatide is not on its drug shortage list or the 503B bulks list, so pharmacies may compound it only under the ordinary limits of sections 503A and 503B; the shortage-era grace periods ended in March 2025.

As of Oct 3, 2026, FDA's drug shortage database lists both semaglutide injection and tirzepatide injection as resolved; FDA declared the tirzepatide shortage over on Dec 19, 2024 and the semaglutide shortage over on Feb 21, 2025.

As of Oct 3, 2026, Medicare covers Wegovy (injection or tablet), Foundayo and the Zepbound KwikPen for weight loss through the temporary Medicare GLP-1 Bridge, for eligible people with Part D, at a $50 monthly copayment.

As of Oct 3, 2026, the Wegovy pill (oral semaglutide) is sold with a prescription through NovoCare Pharmacy at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg self-pay, and Medicare's GLP-1 Bridge covers the tablet.